HUMAN ANTIBODIES AGAINST PD-L1

Claims

The present invention provides antibodies that bind to the programmed cell death ligand-1 (PD-L1) co-inhibitor protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thereby providing a means for treating a disease or disorder such as cancer or viral infection.